Abeona Therapeutics (ABEO) Income towards Parent Company (2011 - 2026)

Abeona Therapeutics' Income towards Parent Company history runs 16 years deep, the most recent figure standing at -$17.1 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 41.95% year-over-year to -$17.1 million in Q1 2026; TTM through Mar 2026 was $66.8 million, a 253.49% increase from a year earlier, with the FY2025 full-year figure at $56.3 million, up 189.31% from the prior year.
• Income towards Parent Company advanced to -$17.1 million in Q1 2026 per ABEO's latest filing, from -$35.3 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $124.3 million in Q2 2025 and bottomed at -$35.3 million in Q4 2025.
• The 5-year median for Income towards Parent Company is -$13.1 million (2022), against an average of -$7.4 million.
• Biggest YoY gain for Income towards Parent Company was 1578.98% in 2025; the steepest drop was 310.15% in 2025.
• Year by year, Income towards Parent Company stood at -$13.1 million in 2022, then declined by 1.56% to -$13.3 million in 2023, then soared by 35.32% to -$8.6 million in 2024, then slumped by 310.15% to -$35.3 million in 2025, then surged by 51.67% to -$17.1 million in 2026.
• Per Business Quant, the three latest ABEO Income towards Parent Company figures stand at -$17.1 million (Q1 2026), -$35.3 million (Q4 2025), and -$5.2 million (Q3 2025).